RT Conference Proceedings
T1 Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
A1 Lacerenza, S.
A1 Moura, D.
A1 Pena-Chilet, M.
A1 Hindi, N.
A1 Dopazo, J.
A1 Sanchez-Bustos, P.
A1 Grignani, G.
A1 Martinez-Trufero, J.
A1 Redondo, A.
A1 Valverde, C.
A1 Stacchiotti, S.
A1 Lopez-Pousa, A.
A1 D'Ambrosio, L.
A1 Perez-Vega, H.
A1 Collini, P.
A1 Lopez-Martin, J. A.
A1 Martin-Broto, J.
K1 Humans
K1 Programmed Cell Death 1 Receptor
K1 Immunotherapy
K1 Angiogenesis
AB Immunomodulation has emerged as an active therapeutic option in some solid tumors; however, the efficacy of immunotherapy-based regimens is limited in sarcomas or restricted to a few specific subtypes. IMMUNOSARC was a phase Ib/II trial testing the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab) in bone and soft-tissue sarcoma (STS). In this latter cohort, the trial met its primary endpoint, with 48% of patients free of progression at 6 months (m). We present here, part of the correlative studies associated with the STS cohort.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27455
UL https://hdl.handle.net/10668/27455
LA en
NO Lacerenza, S., Moura, D., Pena-Chilet, M., Hindi, N., Dopazo, J., Sanchez-Bustos, P., et al. Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups. Ann. Oncol; 2021-09-21; (32); S1118
DS RISalud
RD Apr 8, 2025